Myc targeted CDK18 promotes ATR and homologous recombination to mediate PARP inhibitor resistance in glioblastoma
PARP inhibitors are mainly used to treat BRCA1/2 mutated cancers. Here, the authors show that MYC amplified glioblastomas are sensitive to PARP inhibition due to CDK18 repression, which impairs ATR regulated homologous recombination repair, and that ATR inhibition sensitises glioblastomas to PARP in...
Guardado en:
Autores principales: | Jian-Fang Ning, Monica Stanciu, Melissa R. Humphrey, Joshua Gorham, Hiroko Wakimoto, Reiko Nishihara, Jacqueline Lees, Lee Zou, Robert L. Martuza, Hiroaki Wakimoto, Samuel D. Rabkin |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2019
|
Materias: | |
Acceso en línea: | https://doaj.org/article/403bcdc87a4246559e313ab4b0cb3355 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models
por: Hyoung Kim, et al.
Publicado: (2020) -
Progression through mitosis promotes PARP inhibitor-induced cytotoxicity in homologous recombination-deficient cancer cells
por: Pepijn M. Schoonen, et al.
Publicado: (2017) -
The deubiquitylating enzyme USP15 regulates homologous recombination repair and cancer cell response to PARP inhibitors
por: Yihan Peng, et al.
Publicado: (2019) -
Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancer
por: Neha Chopra, et al.
Publicado: (2020) -
Real-time monitoring of PARP1-dependent PARylation by ATR-FTIR spectroscopy
por: Annika Krüger, et al.
Publicado: (2020)